Literature DB >> 8992872

Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.

X W Meng1, X G Liang, R Birchman, D D Wu, D W Dempster, R Lindsay, V Shen.   

Abstract

When administered intermittently, parathyroid hormone (PTH) is a potent anabolic agent in both human and animal bone. To improve our understanding of this anabolic effect, we have examined the time course of PTH action in an established animal model of estrogen deficiency-induced bone loss: the ovariectomized rat. Animals were ovariectomized (Ovx) and allowed to lose bone for 6 weeks. A dose of 20 micrograms/kg/d of rat PTH (1-34) was administered s.c., 6 days each week for periods of 1, 2, 3, 4, 6 and 8 weeks. Animals were sacrificed for evaluation of skeletal histomorphometry of the proximal tibia and mechanical strength of the cancellous bone in the marrow cavity of the distal femur. Cancellous bone volume (Cn-BV/TV) increased gradually over 8 weeks of treatment (16.8 +/- 1.6 to 24.1 +/- 2.7%) as did the bone formation rate (0.308 +/- 0.054 to 1.659 +/- 0.293 microns3/micron2/d), as determined by an increase in both total mineralization surface (15.5 +/- 2.1 to 42.7 +/- 5.0%) and mineral apposition rate (1.88 +/- 0.20 to 3.55 +/- 0.39 microns/d). The largest increments in these variables reflecting bone formation occurred over the first week of treatment. This bone formation was accompanied by an increase in trabecular thickness (Tb.Th) (55.3 +/- 3.4 to 80.5 +/- 5.0 microns) without a corresponding increment in trabecular number (Tb.N) (3.65 +/- 0.17 to 3.55 +/- 0.26). Extensive tetracycline labels were visualized on the surface of trabecular rod-like and plate-like structures. A small transient, though not statistically significant, increase occurred in both eroded surface and urinary pyridinoline concentration immediately after the onset of PTH administration. Osteocalcin showed a small decrement in the first two weeks after PTH administration, but the levels were elevated when compared with the Ovx control in later weeks. Mechanical strength of the cancellous bone also increased significantly with PTH treatment (20.5 +/- 2.4 to 46.1 +/- 10.0 Newtons). Our results showed that: 1) intermittent PTH treatment of Ovx rats elicited an immediate increase of bone formation activity by the existing osteoblasts, 2) the increase of Cn-BV/TV after PTH administration resulted primarily from an increase in Tb.Th, and 3) improved mechanical strength after PTH treatment can be achieved by increases in Tb.Th without an increase in Tb.N.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8992872     DOI: 10.1002/jbmr.5650110402

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  19 in total

Review 1.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

Review 2.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

3.  In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Authors:  S Hu; C C Liu; G Chen; T Willett; R N Young; M D Grynpas
Journal:  Osteoporos Int       Date:  2015-08-14       Impact factor: 4.507

4.  Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats.

Authors:  Yankel Gabet; David Kohavi; Ralph Müller; Michael Chorev; Itai Bab
Journal:  Osteoporos Int       Date:  2005-04-06       Impact factor: 4.507

5.  Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.

Authors:  T Ishizuya; S Yokose; M Hori; T Noda; T Suda; S Yoshiki; A Yamaguchi
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

6.  The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b.

Authors:  Jau-Yi Li; Lindsey D Walker; Abdul Malik Tyagi; Jonathan Adams; M Neale Weitzmann; Roberto Pacifici
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

7.  Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone.

Authors:  D Yang; R Singh; P Divieti; J Guo; M L Bouxsein; F R Bringhurst
Journal:  Bone       Date:  2007-02-16       Impact factor: 4.398

8.  Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH.

Authors:  Brahmchetna Bedi; Jau-Yi Li; Hesham Tawfeek; Ki-Hyun Baek; Jonathan Adams; Sameera S Vangara; Ming-Kang Chang; Michaela Kneissel; M Neale Weitzmann; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

9.  Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation.

Authors:  Glenda J Pettway; Jeffrey A Meganck; Amy J Koh; Evan T Keller; Steven A Goldstein; Laurie K McCauley
Journal:  Bone       Date:  2007-12-15       Impact factor: 4.398

10.  Effects of PTH treatment on tibial bone of ovariectomized rats assessed by in vivo micro-CT.

Authors:  J E M Brouwers; B van Rietbergen; R Huiskes; K Ito
Journal:  Osteoporos Int       Date:  2009-03-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.